CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock closed at 14.71 per share at the end of the most recent trading day (a 0.75% change compared to the prior day closing price) with a volume of 1.76M shares and market capitalization of 1.44B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. CymaBay Therapeutics Inc. CEO is Sujal Shah.

The one-year performance of CymaBay Therapeutics Inc. stock is 312.43%, while year-to-date (YTD) performance is 134.61%. CBAY stock has a five-year performance of 29.15%. Its 52-week range is between 3.155 and 18.2, which gives CBAY stock a 52-week price range ratio of 76.80%

CymaBay Therapeutics Inc. currently has a PE ratio of -4.70, a price-to-book (PB) ratio of 8.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -80.43%, a ROC of -72.73% and a ROE of -158.16%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CymaBay Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.30 for the next earnings report. CymaBay Therapeutics Inc.’s next earnings report date is 13th Nov 2023.

The consensus rating of Wall Street analysts for CymaBay Therapeutics Inc. is Strong Buy (1), with a target price of $10.25, which is -30.32% compared to the current price. The earnings rating for CymaBay Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CymaBay Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CymaBay Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.46, ATR14 : 0.91, CCI20 : -20.81, Chaikin Money Flow : 0.01, MACD : 0.62, Money Flow Index : 64.12, ROC : 6.36, RSI : 50.70, STOCH (14,3) : 30.20, STOCH RSI : 0.04, UO : 43.35, Williams %R : -69.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CymaBay Therapeutics Inc. in the last 12-months were: Dennis D. Kim (Sold 0 shares of value $-524 837 ), Dennis D. Kim (Sold 120 100 shares of value $1 141 314 ), Mcwherter Charles (Sold 0 shares of value $-217 490 ), Mcwherter Charles (Sold 43 498 shares of value $374 953 ), Quinlan Paul (Sold 0 shares of value $-44 100 ), Quinlan Paul T (Option Exercise at a value of $14 700), Quinlan Paul T (Sold 5 000 shares of value $50 250 )